















BRIEF COMMUNICATION

HLA in isolated REM sleep behavior disorder and Lewy body dementia

Eric Yu^{1,2} , Lynne Krohn^{1,2} , Jennifer A. Ruskey^{2,3}, Farnaz Asayesh^{2,3}, Dan Spiegelman^{2,3}, Zalak Shah⁴, Ruth Chia⁵, Isabelle Arnulf⁶, Michele T. M. Hu^{7,8}, Jacques Y. Montplaisir^{9,10}, Jean-François Gagnon^{9,11}, Alex Desautels^{9,12}, Yves Dauvilliers¹³ , Gian Luigi Gigli^{14,15}, Mariarosaria Valente^{14,15}, Francesco Janes¹⁴, Andrea Bernardini¹⁴ , Birgit Högl¹⁶, Ambra Stefani¹⁶ , Abubaker Ibrahim¹⁶, Anna Heidbreder¹⁷, Karel Sonka¹⁸, Petr Dusek¹⁸, David Kemlink¹⁸, Wolfgang Oertel¹⁹, Annette Janzen¹⁹ , Giuseppe Plazzi^{20,21}, Elena Antelmi²² , Michela Figorilli²³, Monica Puligheddu²³, Brit Mollenhauer^{24,25}, Claudia Trenkwalder^{24,25}, Friederike Sixel-Döring^{19,24}, Valérie Cochen De Cock^{26,27} , Luigi Ferini-Strambi²⁸ , Femke Dijkstra^{29,30,31}, Mineke Viaene^{29,30}, Beatriz Abril³², Bradley F. Boeve³³, Guy A. Rouleau^{1,2,3} , Ronald B. Postuma^{2,3,9} , The International LBD Genomics Consortium, Sonja W. Scholz^{4,34}  & Ziv Gan-Or^{1,2,3}  

¹Department of Human Genetics, McGill University, Montréal, Québec, Canada

²The Neuro (Montréal Neurological Institute-Hospital), McGill University, Montréal, Québec, Canada

³Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada

⁴Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA

⁵Neuromuscular Diseases Research Section, National Institute on Aging, Bethesda, Maryland, USA

⁶Sleep Disorders Unit, Pitié Salpêtrière Hospital, Paris Brain Institute and Sorbonne University, Paris, France

⁷Oxford Parkinson's Disease Centre (OPDC), University of Oxford, Oxford, UK

⁸Division of Neurology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

⁹Center for Advanced Research in Sleep Medicine, Centre Intégré Universitaire de Santé et de Services Sociaux du Nord-de-l'Île-de-Montréal – Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada

¹⁰Department of Psychiatry, Université de Montréal, Montréal, Québec, Canada

¹¹Department of Psychology, Université du Québec à Montréal, Montréal, Québec, Canada

¹²Department of Neurosciences, Université de Montréal, Montréal, Québec, Canada

¹³National Reference Center for Narcolepsy, Sleep Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Inserm U1061, Montpellier, France

¹⁴Clinical Neurology Unit, Department of Neurosciences, University Hospital of Udine, Udine, Italy

¹⁵Department of Medicine (DAME), University of Udine, Udine, Italy

¹⁶Sleep Disorders Clinic, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria

¹⁷Department for Sleep Medicine and Neuromuscular disease, University Hospital Muenster, Muenster, Germany

¹⁸Department of Neurology and Centre of Clinical Neuroscience, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic

¹⁹Department of Neurology, Philipps University, Marburg, Germany

²⁰Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio-Emilia, Modena, Italy

²¹IRCCS, Institute of Neurological Sciences of Bologna, Bologna, Italy

²²Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy

²³Department of Medical Sciences and Public Health, Sleep Disorder Research Center, University of Cagliari, Cagliari, Italy

²⁴Paracelsus-Elena-Klinik, Kassel, Germany

²⁵Department of Neurosurgery, University Medical Centre Göttingen, Göttingen, Germany

²⁶Sleep and Neurology Unit, Beau Soleil Clinic, Montpellier, France

²⁷EuroMov Digital Health in Motion, University of Montpellier IMT Mines Ales, Montpellier, France

²⁸Department of Neurological Sciences, Università Vita-Salute San Raffaele, Milan, Italy

²⁹Laboratory for Sleep Disorders, St. Dimpna Regional Hospital, Geel, Belgium

³⁰Department of Neurology, St. Dimpna Regional Hospital, Geel, Belgium

³¹Department of Neurology, University Hospital Antwerp, Edegem, Antwerp, Belgium

³²Sleep disorder Unit, Carémeau Hospital, University Hospital of Nîmes, Nîmes, France

³³Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA

³⁴Department of Neurology, Johns Hopkins University Medical Center, Baltimore, Maryland, USA

Correspondence

Ziv Gan-Or, Department of Neurology and Neurosurgery, McGill University, 1033 Avenue des Pins O, Room 312, Montréal, QC, Canada. Tel: +1-514-398-5845; Fax: +1-514-398-8248; E-mail: ziv.gan-or@mcgill.ca

Received: 15 June 2023; Accepted: 20 June 2023

Annals of Clinical and Translational Neurology 2023; **10(9)**: 1682–1687

doi: 10.1002/acn3.51841

Abstract

Synucleinopathies-related disorders such as Lewy body dementia (LBD) and isolated/idiopathic REM sleep behavior disorder (iRBD) have been associated with neuroinflammation. In this study, we examined whether the human leukocyte antigen (*HLA*) locus plays a role in iRBD and LBD. In iRBD, *HLA-DRB1**11:01 was the only allele passing FDR correction (OR = 1.57, 95% CI = 1.27–1.93, $p = 2.70 \times 10^{-5}$). We also discovered associations between iRBD and *HLA-DRB1* 70D (OR = 1.26, 95%CI = 1.12–1.41, $p = 8.76 \times 10^{-5}$), 70Q (OR = 0.81, 95%CI = 0.72–0.91, $p = 3.65 \times 10^{-4}$) and 71R (OR = 1.21, 95% CI = 1.08–1.35, $p = 1.35 \times 10^{-3}$). Position 71 ($p_{\text{omnibus}} = 0.00102$) and 70 ($p_{\text{omnibus}} = 0.00125$) were associated with iRBD. Our results suggest that the *HLA* locus may have different roles across synucleinopathies.

Introduction

Isolated/idiopathic REM sleep behavior disorder (iRBD) is a prodromal synucleinopathy characterized by enactment of dreams, vocalization, and absence of muscle atonia during REM sleep.¹ iRBD is one of the strongest predictors for certain neurodegenerative disorders, as approximately 80% of patients will convert to Parkinson's disease (PD), Lewy body dementia (LBD), or multiple system atrophy (MSA) after 10–15 years on average following iRBD diagnosis.²

Previous evidence has shown that iRBD and synucleinopathies share a partial genetic overlap.³ While particular loci (*SNCA*, *GBA*, and *TMEM175*) were shared between these traits, distinct loci such as *LRRK2* and *MAPT* for PD and *APOE* LBD were also identified.³ Furthermore, while the *SNCA* locus is essential in PD, LBD, and iRBD, the association with *SNCA* is driven by different variants for the different traits.³ Similar phenomenon occurs in the *SCARB2* locus, where different variants are associated with PD or RBD.³ Understanding the shared genes and pathways and the genetic differences will lead to better characterization of these disorders. For instance, microglial activation, a form of neuroinflammation, was found in all these disorders.^{4,5} However, the immune system's role in their pathophysiology is poorly understood.

Recently, a fine-mapping study of the human leukocyte antigen (*HLA*) locus in PD demonstrated a strong association of *HLA-DRB1* amino acids 11 V, 13H, and 33H with reduced PD risk.⁶ Located on chromosome 6, the *HLA* locus is a highly polymorphic region with complicated linkage patterns. *HLA* plays an essential role in the adaptive immune system by presenting antigens to T cells.

Since the role of the *HLA* locus is unknown in iRBD and LBD, this study aims to examine whether *HLA* variants may affect the risk for these disorders. We analyzed the association of different *HLA* alleles, haplotypes, and amino acids in two cohorts of iRBD and LBD patients.

Methods**Study population**

iRBD and LBD cohorts from two previous genome-wide association studies (GWAS) were included in this analysis (Table 1).^{3,7} iRBD patients were diagnosed according to the International Classification of Sleep Disorders (2nd or 3rd Edition) with video polysomnography. LBD was diagnosed according to consensus criteria, as described elsewhere.⁷ The LBD cohort was not screened for iRBD. The iRBD cohort is composed of 1072 patients and 9505 controls with genotyping data from the OmniExpress GWAS chip (Illumina Inc.). The control group includes six publicly available cohorts: controls from the International Parkinson's Disease Genomics Consortium (IPDGC) NeuroX dataset (dbGap phs000918.v1.p1), National Institute of Neurological Disorders and Stroke (NINDS) Genome-Wide genotyping in Parkinson's Disease (dbGap phs000089.v4.p2), NeuroGenetics Research Consortium (NGRC) (dbGap phs000196.v3.p1), Parkinson's Progression Markers Initiative (PPMI), and Vance (dbGap phs000394).

The LBD cohort consisted of 2604 patients and 4032 controls with whole-genome sequencing data as described elsewhere.⁷ Study participants signed informed consent forms and the Institutional Review Board at McGill University approved the study protocol.

Quality control

We performed standard GWAS quality control steps for both cohorts using PLINK v1.90. We excluded variants that were heterozygosity outliers ($|F| > 0.15$), sample call rate outliers (< 0.95) and samples failing sex checks were also excluded. We determined genetic ancestry by merging samples with HapMap3 and clustering with principal components analysis (PCA). We only selected samples of European ancestry. A relatedness check was performed

Table 1. Study population after quality control.

Variable	Isolated REM sleep behavior disorder		Lewy body dementia	
	Patients (<i>n</i> = 1072)	Controls (<i>n</i> = 9505)	Patients (<i>n</i> = 2604)	Controls (<i>n</i> = 4032)
Age (years), (SD)	60.54 (11.06)	63.49 (16.59)	74.36 (11.76)	72.63 (16.99)
Male, number (%)	860 (80.22)	4824 (50.75)	1656 (63.59)	1967 (48.78)

n, number; SD, standard deviation.

with GCTA to remove third-degree relatives or closer ones. Then, we performed several variant-level filtrations, such as removing call rate outliers (<0.95) and variants with significantly different missingness between cases and controls ($p < 0.0001$). We also excluded variants that failed PLINK $-test-mishap$ ($p < 0.0001$) and deviated from Hardy–Weinberg equilibrium ($p < 0.0001$) in controls.

HLA imputation

Samples passing quality control were imputed on the Michigan Imputation Server with the four-digit multiethnic HLA reference panel v2⁸ using Minimac4 and phased with Eagle v2.4. This reference panel is composed of five global populations ($n = 20,349$). Only alleles with an imputation score (R^2) above 0.8 were included. We determined HLA haplotypes using haplo.stats R package (<https://analytictools.mayo.edu/research/haplo-stats/>), which employs an Expectation–maximization (EM) algorithm. Using the HLA Genotype Imputation with Attribute Bagging (HIBAG) R package, we imputed HLA amino acids from HLA alleles.⁹

Power calculations

We performed power calculations online for each cohort using CaTS to compute statistical power. (https://csg.sph.umich.edu/abecasis/gas_power_calculator/). We assumed a prevalence of 1% for iRBD¹⁰ and LBD.¹¹ We had enough statistical power (>0.8) to detect an association ($p = 0.0005$) with an odds ratio of 1.33 with a minor allele frequency (MAF) of 0.15. We chose a MAF of 0.15, which correspond to the frequency of *HLA-DRB1* 33H, the amino acid associated with PD. However, we had less than 80% statistical power to detect this association.

Statistical analysis

We performed logistic regression with an additive model on each HLA allele, haplotype and amino acid after adjusting for age at onset, sex and the top 10 principal

components. To test which amino acid position is the most strongly associated with disease risk, we also performed an Omnibus test using the OMNIBUS_LOGISTIC module from HLA-TAPAS.⁸ All rare associations (carrier frequency <1%) were excluded. A 5% false discovery rate (FDR) for multiple testing was applied for alleles ($n = 102$), haplotypes ($n = 105$), and amino acids ($n = 716$) separately.

Results

After HLA imputation, we examined the association of HLA alleles, haplotypes, and amino acids. *HLA-DRB1**11:01 was the only allele passing FDR correction (OR = 1.57, 95% CI = 1.27–1.93, $p = 0.00275$, Table 2). In addition, *HLA-DRB1* 70D, an amino acid encoded by *DRB1**11:01, was associated with iRBD (OR = 1.26, 95% CI = 1.12–1.41, $p = 0.0209$). We also found association with 70Q (OR = 0.81, 95% CI = 0.72–0.91, $p = 0.0441$) and 71R (OR = 1.21, 95% CI = 1.08–1.35, $p = 0.0441$). In *HLA-DRB1*, positions 71 ($p_{\text{omnibus}} = 0.00102$) and 70 ($p_{\text{omnibus}} = 0.00125$) were the most associated with iRBD. *DRB1**11:01 also tags three haplotypes: *DQA1**05:01–*DQB1**03:01–*DRB1**11:01 (OR = 1.40, 95% CI = 1.16–1.70, $p = 0.0285$), *DQA1**05:01–*DRB1**11:01 (OR = 1.41, 95% CI = 1.16–1.72, $p = 0.0285$), and *DQB1**03:01–*DRB1**11:01 (OR = 1.36, 95% CI = 1.13–1.64, $p = 0.0364$).

When we repeated the analysis at one-field (two-digit) resolution, for example, treating *DRB1**11:01 and 11:04 as the same, the association of *DRB1**11 was not significant ($p = 0.12$, Table S1), suggesting that the association was driven solely by the *DRB1**11:01 allele. For LBD, no association was statistically significant after correction for multiple comparisons. We also examined the association of *HLA-DRB1* 33H, which was previously reported to be associated with PD (Table S3).⁶ Although *DRB1* 33H was not associated with iRBD ($p = 0.84$), the MAF frequencies in cases and controls were 0.125 vs. 0.149, respectively. Meanwhile, the *DRB1* 33H allele frequency in both LBD cases and its controls was 0.145 (Table S7). Our results suggest that *DRB1* 33H could be associated with iRBD, but our study lacks the power to detect it.

Table 2. HLA association in isolated REM sleep behavior disorder.

	MAF in cases	MAF in controls	OR	95% CI	<i>p</i>	<i>p</i> (FDR)
Alleles						
<i>HLA-DRB1*11:01</i>	0.0726	0.0472	1.57	1.27–1.93	2.70e-05	2.75e-03
Amino acids						
<i>HLA-DRB1 70D</i>	0.505	0.444	1.26	1.12–1.41	8.76e-05	2.09e-02
<i>HLA-DRB1 70Q</i>	0.440	0.503	0.81	0.72–0.91	3.65e-04	4.41e-02
<i>HLA-DRB1 71R</i>	0.545	0.496	1.21	1.08–1.35	1.35e-03	4.41e-02
Haplotype						
<i>DQA1*05:01–DQB1*03:01–DRB1*11:01</i>	0.0924	0.0657	1.40	1.16–1.70	5.17e-04	2.85e-02
<i>DQA1*05:01–DRB1*11:01</i>	0.0933	0.0652	1.41	1.16–1.72	5.43e-04	2.85e-02
<i>DQB1*03:01–DRB1*11:01</i>	0.0989	0.0707	1.36	1.13–1.64	1.04e-03	3.64e-02

CI, confidence interval; FDR, false discovery rate for each group; MAF, minor allele frequency; OR, odds ratio; *p*, *p*-value.

Discussion

This study shows an association between *DRB1*11:01*, *DRB1 70D*, *70Q*, and *71R* on iRBD. We also identified HLA-*DRB1* positions 71 and 70 via an omnibus test, which suggests that residues at those positions explain a large amount of variance. HLA-*DRB1* position 70–74 is a strong risk factor for rheumatoid arthritis and is referred to as a “shared epitope” (SE).¹² The SE, in combination with *DRB1 11 V*, was associated with a protective effect for PD.¹³ The SE is composed of 70 Q/R and 71 K/R, which are important antigen-binding grooves. Additional studies examining how the SE mediates risk for iRBD will be necessary.

In addition, *DRB1 33H*, a variant also associated with PD, was not significantly associated with iRBD or LBD. However, the difference in carrier frequency between iRBD cases and controls for *DRB1 33H*, similar to that seen in PD, suggests that our study may lack the power to detect this association in iRBD. A recent study has suggested a shared mechanism between PD, AD, amyotrophic lateral sclerosis and HLA-*DRB1*04*, harboring the 33H amino acid change.¹⁴ This subtype was associated with decreased neurofibrillary tangles in post-mortem brains. It also binds to a K311 acetylated Tau PHF6 sequence.¹⁴ These results exemplify the possibility of different HLA types with specific genetic variants that may affect the binding of substrates relevant for neurodegenerative disorders and activating inflammatory response.

We could not replicate the association of a previous study of HLA antigens with 25 iRBD cases. This study showed a significant association between iRBD and *DQB1*05* and *DQB1*06*.¹⁵ The most likely explanation for the discrepancy is that the previous study lacked the power to detect an actual effect. Another study has suggested that HLA-DR expression was associated with iRBD.¹⁶ Fine-mapping and colocalization studies for these findings will be required once larger datasets of iRBD

become available. Whether the mechanism underlying the associations with PD and iRBD is through functional effects of specific amino acid changes or due to different expressions of *HLA* genes in various brain tissues is still to be determined.

Although the immune system’s involvement is still elusive, some potential mechanisms of effect may exist. The varying effects of HLA between RBD and PD could be associated with changing T-cell responses during disease progression. One study showed that alpha-synuclein-specific T-cell responses are high before the development of PD motor symptoms and decline after.¹⁷

Another possibility is that the varying effects between iRBD and PD originate from the brain-first or body-first hypothesis.¹⁸ This model hypothesizes that in brain-first PD, alpha-synuclein originates from the brain and spreads to the peripheral autonomic nervous system. In body-first PD, pathology originates in the gut and spreads to the brain. RBD-positive and negative PD cases were associated with gut-first and brain-first, respectively. HLA alleles may induce a different immune response to brain-first and body-first diseases. Additional mechanisms, which have not been discovered, may be responsible for the association.

Our study has several limitations. First, future replication studies with larger cohorts would be needed to increase statistical power since we do not have a replication cohort. Note that we used the most extensive available cohorts for iRBD and LBD.^{3,7} Although the LBD cohort was composed of Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB) patients, PDD represents only 145 out of 2604 LBD cases. The PDD samples may likely have a minimal effect on the results. Due to the polygenicity of the HLA locus, various populations have different HLA allele frequencies. This study was done only on samples with European ancestry, and multiethnicity analysis could provide more refined evidence on the role of HLA in synucleinopathies.

The cohorts used in the study were also not matched for age and sex. However, we adjusted for these variables in the analysis.

To conclude, we found an alternative *HLA* association of iRBD compared with PD and LBD. More experimental evidence is necessary to characterize the genetic landscape of synucleinopathies and the immune system's role.

Acknowledgements

This work was financially supported by the Canadian Institutes of Health Research (#476751), the Michael J. Fox Foundation, Parkinson's Society Canada, the Canadian Consortium on Neurodegeneration in Aging (CCNA) and the Canada First Research Excellence Fund (CFREF) awarded to McGill University for the Healthy Brains Healthy Lives (HBHL) program. The Montreal iRBD cohort is supported by the Canadian Institutes of Health Research (CIHR). E.Y. is supported by the Canadian Institutes of Health Research (CIHR). J.-F.G. holds a Canada Research Chair on Cognitive Decline in Pathological Aging. Z.G.O. is supported by the Fonds de recherche du Québec Santé (FRQS) Chercheurs boursiers award and is a William Dawson and Killam Scholar. This research was supported in part by the Intramural Research Program of the U.S. National Institutes of Health (National Institute of Neurological Disorders and Stroke; project number: ZIANS003154). This work utilized the computational resources of the NIH HPC Biowulf cluster USA (<http://hpc.nih.gov>). We thank members of the International LBD Genomics Consortium (<https://amp-pd.org/unified-cohorts/lbd#acknowledgements>). A complete list of site investigators and acknowledgments for the International LBD Genomics Consortium is given in the Supplementary Information.

Author Contributions

E.Y. and Z.G.O. contributed to conception and design of the study; E.Y., L.K., J.A.R., F.A., D.S., Z.S., R.C., I.A., M.T.M.H., J.Y.M., J-F.G., A.D., Y.D., G.L.G., M.V., F.J., A.B., B.H., A.S., A.I., A.H., K.S., P.D., D.K., W.O., A.J., G.P., E.A., M.F., M.P., B.M., C.T., F.S.D., V.C.D.C., C.C.M., L.F.S., F.D., M.V., B.A., B.F.B., G.A.R., R.B.P., ILBDGC, and S.W.S. contributed to the acquisition and analysis of data; E.Y. and Z.G.O. contributed to drafting of the manuscript. A full list of ILBDGC members is listed in Table S8.

Conflict of Interest

S.W.S. serves on the Scientific Advisory Council of the Lewy Body Dementia Association and the Multiple

System Atrophy Coalition. S.W.S. receives research support from Cerevel Therapeutics.

Code Availability Statement

All scripts used in this study can be found at https://github.com/gan-orlab/HLA_syn.

Data Availability Statement

Anonymized data not published within this article will be made available by request from any qualified investigator.

References

- Dauvilliers Y, Schenck CH, Postuma RB, et al. REM sleep behaviour disorder. *Nat Rev Dis Primers*. 2018; 4(1):1-16.
- Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain*. 2019; 142(3):744-759.
- Krohn L, Heilbron K, Blauwendraat C, et al. Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects. *Nat Commun*. 2022;13(1):1-16.
- Stokholm MG, Iranzo A, Østergaard K, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. *Lancet Neurol*. 2017;16(10):789-796.
- Amin J, Holmes C, Dorey RB, et al. Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. *Transl Psychiatry*. 2020;10(1):1-11.
- Yu E, Ambati A, Andersen MS, et al. Fine mapping of the HLA locus in Parkinson's disease in Europeans. *Npj Parkinson's Disease*. 2021;7(1):1-7.
- Chia R, Sabir MS, Bandres-Ciga S, et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. *Nat Genet*. 2021;53(3):294-303.
- Luo Y, Kanai M, Choi W, et al. A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. *Nat Genet*. 2021;53(10):1504-1516.
- Zheng X, Shen J, Cox C, et al. HIBAG—HLA genotype imputation with attribute bagging. *Pharmacogenomics J*. 2014;14(2):192-200.
- Haba-Rubio J, Frauscher B, Marques-Vidal P, et al. Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population. *Sleep*. 2017; 41(2):zsx197.
- Desai U, Chandler J, Kirson N, et al. Epidemiology and economic burden of Lewy body dementia in the United States. *Curr Med Res Opin*. 2022;38(7):1177-1188.

12. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum.* 1987;30(11):1205-1213.
13. Hollenbach JA, Norman PJ, Creary LE, et al. A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson's disease. *Proc Natl Acad Sci U S A.* 2019;116(15):7419-7424.
14. Guen YL, Luo G, Ambati A, et al. Protective association of HLA-DRB1*04 subtypes in neurodegenerative diseases implicates acetylated Tau PHF6 sequences. *medRxiv* 2021.12.26.21268354.
15. Schenck CH, Garcia-Rill E, Segall M, Noreen H, Mahowald MW. HLA class II genes associated with REM sleep behavior disorder. *Ann Neurol.* 1996;39(2):261-263.
16. Farmen K, Nissen SK, Stockholm MG, et al. Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. *Proc Natl Acad Sci.* 2021;118(10):e2020858118.
17. Lindestam Arlehamn CS, Dhanwani R, Pham J, et al. α -Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. *Nat Commun.* 2020;11(1):1875.
18. Horsager J, Andersen KB, Knudsen K, et al. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. *Brain.* 2020;143(10):3077-3088.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Tables S1–S7

Table S8